• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ReCode raises $200M series B for next-gen lipid nanoparticle delivery platform

June 29, 2022 By Sean Whooley

ReCode Therapeutics LogoReCode Therapeutics announced today that it closed a Series B extension financing round, adding $120 million in new funds.

Menlo Park, California-based ReCode, which develops the selective organ targeting (SORT) lipid nanoparticle technology (LNP) delivery platform, has now raised $200 million total in the Series B.

New investors Leaps by Bayer (the impact investment unit of Bayer AG) and Ayur Maya (an affiliate of Matrix Capital Management) co-led the round, which also received participation from Amgen Ventures. Matrix Managing Director Dr. Alan Colowick and Leaps by Bayer Senior Director of Venture Investments Health Rakhshita Dhar will join ReCode’s board of directors in connection with the financing.

Pfizer Ventures and EcoR1 Capital led the initial Series B in October 2021, with participation from Sanofi Ventures, Orbimed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures L.P., Osage University Partners, Tekla Capital Management LLC, Superstring Capital, and NS Investment.

ReCode aims to use the proceeds to fund the diversification of its pipeline into central nervous system, liver and oncology indications while advancing its lead mRNA programs for primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into the clinic.

Additionally, funds will be used to advance the development of its platform to deliver a wider range of genetic medicine cargoes, including additional gene correction modalities and small interfering RNA (siRNA) therapies, to a wider range of target cell types in a predictable and programmable fashion.

LNPs package and deliver genetic cargo such as mRNA, going into the blood to be taken up by the liver, limiting utility for broad therapeutics. ReCode said its SORT LNPs are engineered with a biochemically distinct fifth lipid to help the body “sort” and direct the LNPs to other targeted organs like the lung and spleen while being able to bypass the liver if desired.

ReCode said its platform has versatility in its modes of administration, including IV, inhaled, subcutaneous, intramuscular nad intrathecal, as well as in the diversity of genetic cargo to be delivered.

“This potentially game-changing precision medicine technology creates vast possibilities for genetic medicines which have been limited by current technologies,” ReCode Therapeutics CEO and board member Dr. Shehnaaz Suliman said in the release. “With the infusion of new capital and the addition of AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer to our high-caliber board, we are confident that our team will successfully drive ReCode’s mission to develop new precision genetic medicines enabled by superior delivery.”

Filed Under: Business/Financial News, Featured, Funding Roundup, Pharmaceuticals Tagged With: ReCode Therapeutics

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS